Montserrat Martín-Sánchez

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

Esperanza M. Algarín, Andrea Díaz-Tejedor, Pedro Mogollón et al. · Haematologica · 2019 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

Antonio García-Gómez, Tianlu Li, Carlos de la Calle‐Fabregat et al. · Nature Communications · 2021 · 56 citations · Full text

Medicine, Molecular Biology, Oncology +17

The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care

Teresa Paíno, Antonio García-Gómez, Lorena González-Méndez et al. · Clinical Cancer Research · 2016 · 55 citations · Full text

Medicine, Oncology, Pharmacology +15

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi et al. · Journal of Hematology & Oncology · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +16

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

Susana Hernández-García, Laura San‐Segundo, Lorena González-Méndez et al. · Haematologica · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +16